These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24568902)

  • 1. [Management of refractory neuroblastoma with high-dose topotecan plus cyclophosphamide and vincristine].
    Chang J; Zhang YT; Wang LZ; Zhong XD
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):120-3. PubMed ID: 24568902
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.
    Kushner BH; Kramer K; Modak S; Qin LX; Cheung NK
    Cancer; 2010 Jun; 116(12):3054-60. PubMed ID: 20564411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.
    Garaventa A; Luksch R; Biasotti S; Severi G; Pizzitola MR; Viscardi E; Prete A; Mastrangelo S; Podda M; Haupt R; De Bernardi B
    Cancer; 2003 Dec; 98(11):2488-94. PubMed ID: 14635085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: short-term curative effects and toxicity.
    Feng C; Tang S; Wang J; Liu Y; Yang G
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Aug; 33(8):1107-10. PubMed ID: 23996746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
    Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
    BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma.
    Kushner BH; Kramer K; Modak S; Yataghene K; Cheung NK
    Eur J Cancer; 2011 Jan; 47(1):84-9. PubMed ID: 20934323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
    London WB; Frantz CN; Campbell LA; Seeger RC; Brumback BA; Cohn SL; Matthay KK; Castleberry RP; Diller L
    J Clin Oncol; 2010 Aug; 28(24):3808-15. PubMed ID: 20660830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.
    Donfrancesco A; Jenkner A; De Ioris MA; Ilari I; Castellano A; De Laurentis C; Garganese MC; Milano GM; Dominici C
    J Pediatr Hematol Oncol; 2007 Nov; 29(11):799-803. PubMed ID: 17984703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
    Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
    Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
    Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combined chemotherapy with alpha interferon for neuroblastoma].
    Sawada J; Itoi T; Ishii K; Tanaka T; Matsumura T
    Gan To Kagaku Ryoho; 1984 May; 11(5):1147-9. PubMed ID: 6721514
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiagent chemotherapy for children with advanced neuroblastoma. A comparison of high-dose cyclophosphamide, vincristine and adriamycin therapy with James' therapy plus adriamycin.
    Hiyoshi Y; Yano H; Tanaka T; Noguchi A; Horikoshi T; Irie Y
    Kurume Med J; 1984; 31(1):1-6. PubMed ID: 6482368
    [No Abstract]   [Full Text] [Related]  

  • 14. Carboplatin activity in cisplatin treated neuroblastoma.
    Lewis IJ; Stevens MC; Pearson AD; Pinkerton CR; Barnes JM
    Prog Clin Biol Res; 1991; 366():553-9. PubMed ID: 2068173
    [No Abstract]   [Full Text] [Related]  

  • 15. Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series.
    Li Y; Feng C; Chen Y; Huang K; Li C; Xiong X; Li P; Zhou D; Peng X; Weng W; Deng X; Wu Y; Fang J
    Technol Cancer Res Treat; 2021; 20():15330338211041454. PubMed ID: 34569870
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effectiveness of chemotherapy of advanced forms of neuroblastoma in children according to the program of the RWPG].
    Bozek J; Perek D
    Pediatr Pol; 1984 Nov; 59(11):943-8. PubMed ID: 6399098
    [No Abstract]   [Full Text] [Related]  

  • 17. Antitumor activity of nifurtimox observed in a patient with neuroblastoma.
    Saulnier Sholler GL; Kalkunte S; Greenlaw C; McCarten K; Forman E
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):693-5. PubMed ID: 17023833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.
    Kushner BH; Kramer K; Modak S; Cheung NK
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):84-7. PubMed ID: 14734455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
    Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
    J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
    Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
    Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.